{
    "organizations": [],
    "uuid": "24e7ece98f043668b3528fcb1e73a99858345efd",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/30/globe-newswire-portola-pharmaceuticals-to-announce-first-quarter-2018-financial-results-and-host-conference-call-on-wednesday-may-9-2018.html",
    "ord_in_thread": 0,
    "title": "Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2018, and provide a general business overview on Wednesday, May 9, 2018, at 4:30 p.m. ET (1:30 p.m. PT).\nConference Call Details\nThe live conference call on Wednesday, May 9, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 7068059. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com . It will be archived for 30 days following the call.\nAbout Portola Pharmaceuticals, Inc.\nPortola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa ® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.\nInvestor Contact:\nCara Miller\nPortola Pharmaceuticals\nir@portola.com\nMedia Contact:\nLaurie Masonson\nPure Communications\nlmasonson@purecommunications.com\nSource:Portola Pharmaceuticals, Inc.",
    "published": "2018-05-01T00:30:00.000+03:00",
    "crawled": "2018-05-01T02:00:25.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "south",
        "san",
        "francisco",
        "april",
        "globe",
        "newswire",
        "portola",
        "pharmaceutical",
        "nasdaq",
        "ptla",
        "announced",
        "today",
        "host",
        "webcast",
        "conference",
        "call",
        "discus",
        "company",
        "financial",
        "result",
        "quarter",
        "ended",
        "march",
        "provide",
        "general",
        "business",
        "overview",
        "wednesday",
        "may",
        "et",
        "pt",
        "conference",
        "call",
        "detail",
        "live",
        "conference",
        "call",
        "wednesday",
        "may",
        "et",
        "accessed",
        "phone",
        "calling",
        "united",
        "state",
        "canada",
        "internationally",
        "using",
        "passcode",
        "webcast",
        "accessed",
        "live",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "http",
        "archived",
        "day",
        "following",
        "call",
        "portola",
        "pharmaceutical",
        "portola",
        "pharmaceutical",
        "biopharmaceutical",
        "company",
        "developing",
        "product",
        "candidate",
        "could",
        "significantly",
        "advance",
        "field",
        "thrombosis",
        "hematologic",
        "disease",
        "company",
        "first",
        "medicine",
        "bevyxxa",
        "betrixaban",
        "oral",
        "factor",
        "xa",
        "inhibitor",
        "approved",
        "food",
        "drug",
        "administration",
        "june",
        "company",
        "also",
        "working",
        "advance",
        "two",
        "clinical",
        "program",
        "andexanet",
        "alfa",
        "recombinant",
        "protein",
        "designed",
        "reverse",
        "anticoagulant",
        "effect",
        "patient",
        "treated",
        "oral",
        "injectable",
        "factor",
        "xa",
        "inhibitor",
        "cerdulatinib",
        "inhibitor",
        "development",
        "treat",
        "hematologic",
        "cancer",
        "portola",
        "partnered",
        "program",
        "focused",
        "developing",
        "selective",
        "syk",
        "inhibitor",
        "inflammatory",
        "condition",
        "information",
        "visit",
        "http",
        "follow",
        "company",
        "twitter",
        "investor",
        "contact",
        "cara",
        "miller",
        "portola",
        "pharmaceutical",
        "ir",
        "medium",
        "contact",
        "laurie",
        "masonson",
        "pure",
        "communication",
        "lmasonson",
        "source",
        "portola",
        "pharmaceutical",
        "inc"
    ]
}